ASH News Daily - Sunday, December 11, 2011 - (Page B-30)

Page B–30 ® ASH NewS DAily Sunday, December 11, 2011 Graduate Student From Kyoto University Receives Honor for Highest-Scoring Abstract T his year’s recipient of the Mary Rodes Gibson Memorial Award in Hemostasis and Thrombosis is Sou Nakamura, a graduate student from the Center for IPS Cell Research and Application at Kyoto University in Japan. Mr. Nakamura is currently working in the laboratory of Dr. Koji Eto. His abstract, “Platelet Production System Using an Immortalized Megakaryocyte Cell Line Derived From Human Pluripotent Stem Cells,” will be presented by Dr. Naoya Takayama, second author of the abstract, during the Plenary Sci- tion Center, Ballroom 20D. entific Session at 2:00 p.m. in Hall AB The Mary Rodes Gibson Memoat the San Diego Conrial Award in Hemovention Center.” stasis and Thrombosis In addition, Mr. Nawas established in 2006 kamura is invited to to recognize the trainee present his abstract (undergraduate studuring the Special dent, medical student, Symposium on the Bagraduate student, resisic Science of Hemostadent physician, or postsis and Thrombosis on doctoral fellow) who Tuesday, December 13, is the first author and from 7:30 to 9:00 a.m. at presenter of the highthe San Diego Conven- Sou Nakamura est-scoring abstract submitted in the field of hemostasis and thrombosis. This award is made possible by the Mary Rodes Gibson Hemostasis-Thrombosis Foundation to continue the legacy of Mary Rodes Gibson who suffered from severe, type 3 von Willebrand disease. Special Symposium on the Basic Science of Hemostasis and Thrombosis Tuesday, December 13 7:30 - 9:00 a.m. SDCC, Ballroom 20D Hodgkin lymphoma— ≈10% refractory rates1 ≈ 30% relapse rates after complete response1 ≈ 50% of transplants fail2,3 Long-term health complications4 Reduced survival in some patients initially cured5 NoGoodCancer.com Visit us at ASH booth 129 References 1. Quddus F, Armitage JO. Salvage therapy for Hodgkin’s lymphoma. Cancer J. 2009;15(2):161-163. 2. Sureda A, Constans M, Iriondo A, et al; The Grupo Español de Linfomas/Transplante Autólogo de Médula Osea (GEL/TAMO) Cooperative Group. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol. 2005;16(4):625-633. 3. Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006;12(10):1065-1072. 4. Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol. 2003;21(18):3431-3439. 5. Martinez C, Canals C, Alessandrino E, et al; Lymphoma Working Party of the EBMT. Relapse of Hodgkin’s lymphoma (HL) after autologous stem cell transplantation (ASCT): prognostic factors in 462 patients registered in the database of the EBMT. J Clin Oncol. 2010;28(15)(suppl):8060. Seattle Genetics and are US registered trademarks of Seattle Genetics, Inc. © 2011 Seattle Genetics, Inc., Bothell, WA 98021 All rights reserved US/BVP/2011/0138 003192_sgn35_ngc_and_fa1.indd 1 10/24/11 1:14 PM 

Table of Contents for the Digital Edition of ASH News Daily - Sunday, December 11, 2011

ASH News Daily - Sunday, December 11, 2011

https://www.nxtbookmedia.com